MedTrace Logo

Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

NCT06114953 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2023-11-02

No results posted yet for this study

Summary

This prospective, randomized controlled study is intended to enroll 152 patients in the early stages of donor kidney transplantation at six clinical centers in China between January 2023 and January 2024. All patients meeting the inclusion criteria were randomly assigned 1:1 to either Mizoribine or Mycophenolate Mofetil for 12 months. At the baseline of follow-up (before enrollment) and each follow-up point, all clinical indicators of patients were recorded to measure the therapeutic effect.

Conditions

  • Kidney Transplant Immunosuppression

Interventions

DRUG

Mizoribine

Mizoribine+glucocorticoid+tacrolimus after kidney transplantation

DRUG

Mycophenolate Mofetil

Mycophenolate Mofetil+glucocorticoid+tacrolimus after kidney transplantation

Sponsors & Collaborators

  • Lee's Pharmaceutical Limited

    lead INDUSTRY

Principal Investigators

  • TAO LIN, Doctor · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2025-01-01
Completion
2025-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06114953 on ClinicalTrials.gov